Back to Search
Start Over
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
- Source :
-
Blood [Blood] 2021 Dec 16; Vol. 138 (24), pp. 2589-2592. - Publication Year :
- 2021
- Subjects :
- Adenine therapeutic use
Aged
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Chromosome Deletion
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Male
Middle Aged
Mutation drug effects
Remission Induction
Rituximab therapeutic use
Adenine analogs & derivatives
Chromosomes, Human, Pair 17 genetics
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Piperidines therapeutic use
Protein Kinase Inhibitors therapeutic use
Tumor Suppressor Protein p53 genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 138
- Issue :
- 24
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Report
- Accession number :
- 34521099
- Full Text :
- https://doi.org/10.1182/blood.2021012315